Skip to main content

11-04-2010 | Diabetes | Article

Glycemic control and obesity influence aspirin resistance in Type 2 diabetics


Free abstract

MedWire News: Poor glycemic control, obesity, and lower aspirin dose are associated with increased risk for aspirin resistance (AR) in Type 2 diabetics, report Turkish researchers.

Aspirin is commonly used as an antiplatelet agent to reduce the risk for cardiovascular disease in at-risk individuals such as those with Type 2 diabetes.

AR, involving the inability of the drug to reduce platelet activation and aggregation through inhibition of the cyclooxygenase-1-mediated thromboxane A2 pathway, has been associated with increased risk for cardiovascular disease and is more common in diabetic than nondiabetic individuals.

Taner Ertugrul (Kecioren Research and Training Hospital, Ankara) and colleagues therefore investigated factors predicting AR in 108 diabetic patients and 67 nondiabetic individuals.

The researchers used area under the receiver operating characteristic curve (AUC) to measure aggregation response. An AUC score of 300 or more was used to define AR.

They report in the Journal of Clinical Endocrinology and Metabolism that for the whole cohort, body mass index (BMI), fasting blood glucose, and glycated hemoglobin (HbA1c) levels were significantly positively correlated with AR.

Diabetic participants were a significant 30% more likely to be aspirin resistant than nondiabetics. They also had higher alanine aminotransferase and BMI, and lower levels of high-density lipoprotein cholesterol than nondiabetic participants.

Use of low-dose aspirin (100 mg/day vs 300 mg/day) also increased the risk for AR, by 26% in diabetics and by 30% overall.

“These data suggest that glycemic control, obesity, and the dose of aspirin have influence on AR in diabetic subjects,” conclude the authors.

They add: “Further studies with larger groups are needed to clarify the role of glycemic control on AR.”

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Helen Albert